Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ESPR

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ESPR
DateTimeSourceHeadlineSymbolCompany
19/07/202422:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
19/07/202422:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
18/07/202405:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
18/07/202405:11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
16/07/202422:00GlobeNewswire Inc.New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their ArteriesNASDAQ:ESPREsperion Therapeutics Inc
28/06/202421:00GlobeNewswire Inc.Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest FacilityNASDAQ:ESPREsperion Therapeutics Inc
19/06/202405:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
19/06/202405:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
29/05/202406:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
25/05/202406:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
25/05/202406:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
25/05/202406:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
23/05/202423:00GlobeNewswire Inc.Esperion to Participate in Upcoming June Investor ConferencesNASDAQ:ESPREsperion Therapeutics Inc
22/05/202422:00GlobeNewswire Inc.First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular RiskNASDAQ:ESPREsperion Therapeutics Inc
21/05/202406:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
20/05/202420:00GlobeNewswire Inc.Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for HypercholesterolemiaNASDAQ:ESPREsperion Therapeutics Inc
18/05/202405:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
14/05/202422:00GlobeNewswire Inc.Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®NASDAQ:ESPREsperion Therapeutics Inc
11/05/202406:00GlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
09/05/202406:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
07/05/202422:50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ESPREsperion Therapeutics Inc
07/05/202421:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
07/05/202420:00GlobeNewswire Inc.Esperion Reports First Quarter 2024 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
29/04/202422:00GlobeNewswire Inc.Esperion to Participate in Upcoming May Investor ConferencesNASDAQ:ESPREsperion Therapeutics Inc
23/04/202422:00GlobeNewswire Inc.Esperion to Report First Quarter 2024 Financial Results on May 7NASDAQ:ESPREsperion Therapeutics Inc
08/04/202404:45GlobeNewswire Inc.Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesityNASDAQ:ESPREsperion Therapeutics Inc
01/04/202423:00GlobeNewswire Inc.Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024NASDAQ:ESPREsperion Therapeutics Inc
26/03/202423:00GlobeNewswire Inc.Esperion to Participate in 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
26/03/202407:00GlobeNewswire Inc.Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24NASDAQ:ESPREsperion Therapeutics Inc
23/03/202409:26Business WireU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin UseNASDAQ:ESPREsperion Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ESPR